GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells

Biochimica Et Biophysica Acta. Molecular Cell Research
Przemysław DudaJames A McCubrey

Abstract

Glycogen synthetase kinase-3 (GSK-3) and microRNAs (miRs) affect many critical signaling pathways important in cell growth. GSK-3 is a serine/threonine (S/T) protein kinase. Often when GSK-3 phosphorylates other proteins, they are inactivated and the signaling pathway is shut down. The PI3K/PTEN/AKT/GSK3/mTORC1 pathway plays key roles in regulation of cell growth, apoptosis, drug resistance, malignant transformation and metastasis and is often deregulated in cancer. When GSK-3 is phosphorylated by AKT it is inactivated and this often leads to growth promotion. When GSK-3 is not phosphorylated by AKT or other kinases at specific negative-regulatory residues, it can modify the activity of many proteins by phosphorylation, some of these proteins promote while others inhibit cell proliferation. This is part of the conundrum regarding GSK-3. The central theme of this review is the ability of GSK-3 to serve as either a tumor suppressor or a tumor promoter in cancer which is likely due to its diverse protein substrates. The effects of multiple miRs which bind mRNAs encoding GSK-3 and other signaling molecules and how they affect cell growth and sensitivity to various therapeutics will be discussed as they serve to regulate GSK-3 and o...Continue Reading

References

Oct 18, 2000·Proceedings of the National Academy of Sciences of the United States of America·X FangG B Mills
Feb 22, 2005·International Journal of Cancer. Journal International Du Cancer·Esra ErdalMehmet Ozturk
Jul 27, 2005·Biochemical and Biophysical Research Communications·Abbas ShakooriToshinari Minamoto
Dec 24, 2005·The Journal of Biological Chemistry·Alexandra ThielAri Ristimäki
Nov 15, 2006·Current Drug Targets·Lisa KockeritzJames R Woodgett
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Munekazu YamakuchiCharles J Lowenstein
Sep 17, 2008·Laboratory Investigation; a Journal of Technical Methods and Pathology·Zhiyu ZhangHong Lu
Feb 18, 2009·Cell Cycle·Munekazu Yamakuchi, Charles J Lowenstein
Jul 25, 2009·The American Journal of Pathology·Liying ZhangWilliam L Gerald
Feb 11, 2011·Aging·Vincenzo Calvanese, Mario F Fraga
Mar 23, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Huizhi WangMichael Martin
Nov 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sejeong ShinSang-Oh Yoon
May 17, 2012·Cancer Research·Ian A PriorCarla Mattos
Jun 13, 2012·Expert Opinion on Therapeutic Targets·Alberto M MartelliJames A McCubrey
Oct 31, 2013·Advances in Biological Regulation·James A McCubreyLinda S Steelman
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Eleanor Y ChenDavid M Langenau
Jun 17, 2014·Oncotarget·James A McCubreyMelchiorre Cervello
Jul 30, 2014·Molecular Medicine Reports·Xiaoyun ZhaoJian Li
Aug 16, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Guanghui HuYunfei Xu
Sep 2, 2014·Molecular Cancer·Jack W RostasRajeev S Samant
Nov 5, 2014·Cancer Research·Eun Young ParkJong Hoon Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

Advances in Biological Regulation
Miguel A HermidaNick R Leslie
Advances in Biological Regulation
James A McCubrey, Lucio Cocco
© 2022 Meta ULC. All rights reserved